MabVax Therapeutics announces $1.25 million registered direct offering
MabVax Therapeutics announced that it has agreed to sell approximately 2.0 million shares of its common stock for gross proceeds $1.25 million. Each share of common stock is being sold at a price of $0.62 per share. The offering is expected to close Sept. 27, 2017. September 22, 2017